arrow
U

Uzma Sarwar

Pfizer Inc
H指数:21
被引数:3,256

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study
2026-01-290
OAAI
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial

MATISSE (母体预防接种安全性和有效性研究) 母体呼吸道合胞病毒Prefusion F蛋白疫苗试验的有效性,安全性和免疫原性

2025-01-022
PRE
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine

二价呼吸道合胞病毒Prefusion F蛋白疫苗的MATISSE (安全性和有效性孕产妇预防接种研究) 孕产妇试验的早产频率和相关结果

2025-01-021
PRE
Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions

双价RSVpreF疫苗在18至 <60岁高危人群中的应用

2024-11-112
PRE
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

BNT162b2新型冠状病毒肺炎疫苗在5岁以下儿童中的应用评价

2023-02-1645
OAAI
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
2022-01-06432
OAAI
Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units

在重症监护病房中引入专门的传染病-重症监护医学服务后的临床结果评估

2021-04-150
OAAI
Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC
2021-01-2125
OAAI
Early Infectious Disease Consultation Is Associated With Lower Mortality in Patients With Severe Sepsis or Septic Shock Who Complete the 3-Hour Sepsis Treatment Bundle

在完成3小时脓毒症治疗包的严重脓毒症或脓毒症休克患者中,早期传染病会诊与较低的死亡率相关

2019-10-3128
OAAI
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (vol 22, pg 614, 2016)
2016-06-071
PREAI
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
2016-05-09288
PREAI
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
LANCET
IF88.5
2014-12-01213
PREAI